1.

Imatinib Adherence and Persistence in Patients with Chronic Myeloid Leukemia in Belgium: Evidence from Real-World Data

2.

Imatinib Adherence and Persistence in Patients with Chronic Myeloid Leukemia in Belgium: Evidence from Real-World Data

1.

Disease characteristics in Belgian myelofibrosis patients and management guidelines anno 2013

2.

Disease characteristics in Belgian myelofibrosis patients and management guidelines anno 2013

3.

Disease characteristics in Belgian myelofibrosis patients and management guidelines anno 2013

1.

Practical management of chronic myeloid leukemia in Belgium

2.

Practical management of chronic myeloid leukemia in Belgium

3.

Practical management of chronic myeloid leukemia in Belgium

1.

Sequential administration of 5-azacytidine (AZA) and donor lymphocyte infusion (DLI) for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) in relapse aft...

1.

Non-myeloablative allogeneic hematopoietic cell transplantation following fludarabine plus 2 Gy TBI or ATG plus 8 Gy TLI: a phase II randomized study from the Belgian Hematological...

2.

Non-myeloablative allogeneic hematopoietic cell transplantation following fludarabine plus 2 Gy TBI or ATG plus 8 Gy TLI: a phase II randomized study from the Belgian Hematological...

3.

Non-myeloablative allogeneic hematopoietic cell transplantation following fludarabine plus 2 Gy TBI or ATG plus 8 Gy TLI: a phase II randomized study from the Belgian Hematological...

4.

Non-myeloablative allogeneic hematopoietic cell transplantation following fludarabine plus 2 Gy TBI or ATG plus 8 Gy TLI: a phase II randomized study from the Belgian Hematological...

5.

Non-myeloablative allogeneic hematopoietic cell transplantation following fludarabine plus 2 Gy TBI or ATG plus 8 Gy TLI: a phase II randomized study from the Belgian Hematological...

6.

Non-myeloablative allogeneic hematopoietic cell transplantation following fludarabine plus 2 Gy TBI or ATG plus 8 Gy TLI: a phase II randomized study from the Belgian Hematological...

7.

Non-myeloablative allogeneic hematopoietic cell transplantation following fludarabine plus 2 Gy TBI or ATG plus 8 Gy TLI: a phase II randomized study from the Belgian Hematological...

1.

Nonmyeloablative allogeneic hematopoietic cell transplantation following Fludarabine Plus 2 Gy TBI or ATG Plus 8 Gy TLI: a phase II randomized study from the Belgian Hematological...

1.

Non-myeloablative allogeneic hematopoietic cell transplantation following fludarabine plus 2 Gy TBI or ATG plus 8 Gy TLI: A phase II randomized study from the belgian hematological...

1.

Use of chimerism analysis after allogeneic stem cell transplantation: Belgian guidelines and review of the current literature

1.

Use of chimerism analysis after allogeneic stem cell transplantation: Belgian guidelines and review of the current literature.

2.

Use of chimerism analysis after allogeneic stem cell transplantation: Belgian guidelines and review of the current literature.

3.

Use of chimerism analysis after allogeneic stem cell transplantation: Belgian guidelines and review of the current literature.

1.

Sequential administration of low dose 5-azacytidine (AZA) and donor lymphocyte infusion (DLI) for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) in re...

2.

Sequential administration of low dose 5-azacytidine (AZA) and donor lymphocyte infusion (DLI) for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) in re...

3.

Sequential administration of low dose 5-azacytidine (AZA) and donor lymphocyte infusion (DLI) for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) in re...